7 Day Study of Mast Cell Inhibitor, R926112, in Patients With Symptomatic Seasonal Allergic Rhinitis
Status:
Completed
Trial end date:
2005-09-01
Target enrollment:
Participant gender:
Summary
This is a study of the effectiveness and safety of a new nasal spray for the relief of the
symptoms of seasonal allergies. The agents being compared are: R926112 (a novel anti-allergy
medicine), Beconase (beclomethasone dipropionate, an established FDA approved steroid
treatment), and an inactive placebo. The study hypothesis is that R926112 will be superior to
placebo at the end of a week of testing and evaluation. The study does not have the power to
determine how R926112 compares to Beconase.